4 Weeks Treatment of Type II Diabetic Patients With BI 44847

Summary

The primary objective of the current study is to investigate the safety and tolerability of BI 44847 in male and female patients with type 2 diabetes following oral administration of repeated doses of 100 mg b.i.d, 400 mg b.i.d. and 800 mg b.i.d. over 28 days. A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI 44847 after multiple dosing, including assessment of steady state.

Timeline

Start

2007-06

Primary completion

2007-11

Completion

—

Drugs

Indications